Trade Biomea Fusion, Inc. - BMEA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.24 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biomea Fusion Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 12.7 |
Open* | 13.16 |
1-Year Change* | 87.2% |
Day's Range* | 12.61 - 13.16 |
52 wk Range | 6.04-43.69 |
Average Volume (10 days) | 457.51K |
Average Volume (3 months) | 9.64M |
Market Cap | 354.92M |
P/E Ratio | -100.00K |
Shares Outstanding | 35.71M |
Revenue | N/A |
EPS | -3.34 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 29, 2023 | 12.70 | -1.81 | -12.47% | 14.51 | 15.08 | 12.69 |
Nov 28, 2023 | 9.89 | 0.01 | 0.10% | 9.88 | 9.98 | 9.46 |
Nov 27, 2023 | 9.91 | -0.14 | -1.39% | 10.05 | 10.37 | 9.71 |
Nov 24, 2023 | 10.21 | 0.26 | 2.61% | 9.95 | 10.42 | 9.91 |
Nov 22, 2023 | 9.97 | 0.10 | 1.01% | 9.87 | 10.26 | 9.71 |
Nov 21, 2023 | 9.88 | -0.10 | -1.00% | 9.98 | 10.14 | 9.60 |
Nov 20, 2023 | 10.26 | 0.03 | 0.29% | 10.23 | 10.95 | 10.11 |
Nov 17, 2023 | 10.32 | 1.29 | 14.29% | 9.03 | 10.81 | 8.96 |
Nov 16, 2023 | 9.25 | -0.51 | -5.23% | 9.76 | 9.76 | 8.88 |
Nov 15, 2023 | 9.25 | 0.48 | 5.47% | 8.77 | 10.20 | 8.77 |
Nov 14, 2023 | 8.84 | 0.37 | 4.37% | 8.47 | 9.02 | 8.41 |
Nov 13, 2023 | 8.31 | -0.02 | -0.24% | 8.33 | 8.34 | 8.06 |
Nov 10, 2023 | 8.43 | -0.08 | -0.94% | 8.51 | 8.59 | 8.09 |
Nov 9, 2023 | 8.55 | -0.37 | -4.15% | 8.92 | 9.18 | 8.54 |
Nov 8, 2023 | 9.01 | -0.27 | -2.91% | 9.28 | 9.28 | 8.72 |
Nov 7, 2023 | 9.26 | 0.25 | 2.77% | 9.01 | 9.71 | 9.00 |
Nov 6, 2023 | 9.23 | -0.82 | -8.16% | 10.05 | 10.05 | 9.06 |
Nov 3, 2023 | 10.02 | 0.15 | 1.52% | 9.87 | 10.44 | 9.86 |
Nov 2, 2023 | 10.00 | -0.41 | -3.94% | 10.41 | 11.14 | 9.76 |
Nov 1, 2023 | 10.39 | 0.51 | 5.16% | 9.88 | 10.39 | 9.74 |
Biomea Fusion, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 |
Total Operating Expense | 83.634 | 41.667 | 5.327 | 1.195 |
Selling/General/Admin. Expenses, Total | 20.921 | 13.671 | 1.656 | 0.103 |
Research & Development | 62.713 | 27.996 | 3.671 | 1.092 |
Operating Income | -83.634 | -41.667 | -5.327 | -1.195 |
Interest Income (Expense), Net Non-Operating | 1.806 | 0.1 | 0.003 | -0.003 |
Net Income Before Taxes | -81.828 | -41.567 | -5.324 | -1.198 |
Net Income After Taxes | -81.828 | -41.567 | -5.324 | -1.198 |
Net Income Before Extra. Items | -81.828 | -41.567 | -5.324 | -1.198 |
Net Income | -81.828 | -41.567 | -5.324 | -1.198 |
Income Available to Common Excl. Extra. Items | -81.828 | -41.567 | -5.324 | -1.198 |
Income Available to Common Incl. Extra. Items | -81.828 | -41.567 | -5.324 | -1.198 |
Diluted Net Income | -81.828 | -41.567 | -5.324 | -1.198 |
Diluted Weighted Average Shares | 29.2718 | 23.8585 | 28.7679 | 28.7679 |
Diluted EPS Excluding Extraordinary Items | -2.79546 | -1.74223 | -0.18507 | -0.04164 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Diluted Normalized EPS | -2.79546 | -1.74223 | -0.18507 | -0.04164 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 27.657 | 30.031 | 26.276 | 23.484 | 17.474 |
Selling/General/Admin. Expenses, Total | 5.719 | 5.636 | 5.737 | 5.242 | 4.892 |
Research & Development | 21.938 | 24.395 | 20.539 | 18.242 | 12.582 |
Operating Income | -27.657 | -30.031 | -26.276 | -23.484 | -17.474 |
Interest Income (Expense), Net Non-Operating | 2.766 | 0.98 | 0.962 | 0.594 | 0.216 |
Net Income Before Taxes | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Net Income After Taxes | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Net Income Before Extra. Items | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Net Income | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Income Available to Common Excl. Extra. Items | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Income Available to Common Incl. Extra. Items | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Diluted Net Income | -24.891 | -29.051 | -25.314 | -22.89 | -17.258 |
Diluted Weighted Average Shares | 35.3483 | 29.5865 | 29.4435 | 29.319 | 29.1964 |
Diluted EPS Excluding Extraordinary Items | -0.70416 | -0.9819 | -0.85975 | -0.78072 | -0.5911 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.70416 | -0.9819 | -0.85975 | -0.78072 | -0.5911 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 117.819 | 176.561 | 62.223 | 0.265 |
Cash and Short Term Investments | 113.049 | 173.516 | 61.695 | 0.239 |
Cash & Equivalents | 111.899 | 145.736 | 61.695 | 0.239 |
Prepaid Expenses | 4.77 | 3.045 | 0.492 | 0.015 |
Other Current Assets, Total | 0.036 | 0.011 | ||
Total Assets | 129.307 | 185.705 | 62.526 | 0.265 |
Property/Plant/Equipment, Total - Net | 7.992 | 5.687 | 0.291 | 0 |
Property/Plant/Equipment, Total - Gross | 8.908 | 5.944 | 0.299 | 0 |
Accumulated Depreciation, Total | -0.916 | -0.257 | -0.008 | 0 |
Other Long Term Assets, Total | 3.496 | 1.581 | 0.012 | 0 |
Total Current Liabilities | 19.101 | 4.637 | 1.619 | 0.286 |
Accounts Payable | 6.826 | 1.329 | 0.727 | 0.271 |
Accrued Expenses | 11.639 | 2.828 | 0.856 | 0.015 |
Notes Payable/Short Term Debt | 0 | 0 | 0.036 | 0 |
Total Liabilities | 20.768 | 6.922 | 1.619 | 0.286 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Total Equity | 108.539 | 178.783 | 60.907 | -0.021 |
Preferred Stock - Non Redeemable, Net | 0 | 55.738 | 0 | |
Common Stock | 0.003 | 0.003 | 0.001 | 0.001 |
Additional Paid-In Capital | 240.107 | 228.532 | 13.343 | 2.829 |
Retained Earnings (Accumulated Deficit) | -131.57 | -49.742 | -8.175 | -2.851 |
Total Liabilities & Shareholders’ Equity | 129.307 | 185.705 | 62.526 | 0.265 |
Total Common Shares Outstanding | 29.5616 | 29.1156 | 28.7679 | 28.7679 |
Short Term Investments | 1.15 | 27.78 | ||
Long Term Investments | 0 | 1.876 | ||
Other Current Liabilities, Total | 0.636 | 0.48 | ||
Other Liabilities, Total | 1.667 | 2.285 | ||
Other Equity, Total | -0.001 | -0.01 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 202.504 | 225.936 | 88.931 | 117.819 | 138.861 |
Cash and Short Term Investments | 199.09 | 222.908 | 86.3 | 113.049 | 133.458 |
Cash & Equivalents | 199.09 | 222.908 | 86.3 | 111.899 | 132.311 |
Short Term Investments | 0 | 0 | 0 | 1.15 | 1.147 |
Total Receivables, Net | |||||
Accounts Receivable - Trade, Net | |||||
Prepaid Expenses | 3.414 | 3.028 | 2.631 | 4.77 | 5.403 |
Other Current Assets, Total | |||||
Total Assets | 225.087 | 248.674 | 112.638 | 129.307 | 145.05 |
Property/Plant/Equipment, Total - Net | 17.385 | 18.481 | 19.467 | 7.992 | 5.345 |
Property/Plant/Equipment, Total - Gross | 19.396 | 20.073 | 20.676 | 8.908 | 6.078 |
Accumulated Depreciation, Total | -2.011 | -1.592 | -1.209 | -0.916 | -0.733 |
Long Term Investments | 0 | 0.01 | |||
Other Long Term Assets, Total | 5.198 | 4.257 | 4.24 | 3.496 | 0.834 |
Total Current Liabilities | 16.21 | 14.357 | 18.774 | 19.101 | 12.589 |
Accounts Payable | 3.194 | 4.154 | 5.329 | 6.826 | 1.592 |
Accrued Expenses | 12.852 | 9.804 | 13.02 | 11.639 | 10.569 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.164 | 0.399 | 0.425 | 0.636 | 0.428 |
Total Liabilities | 25.475 | 24.369 | 29.509 | 20.768 | 14.415 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 199.612 | 224.305 | 83.129 | 108.539 | 130.635 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Common Stock | 0.004 | 0.004 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 413.549 | 409.813 | 243.747 | 240.107 | 236.901 |
Retained Earnings (Accumulated Deficit) | -213.941 | -185.512 | -160.621 | -131.57 | -106.256 |
Other Equity, Total | 0 | 0 | 0 | -0.001 | -0.013 |
Total Liabilities & Shareholders’ Equity | 225.087 | 248.674 | 112.638 | 129.307 | 145.05 |
Total Common Shares Outstanding | 35.6988 | 35.6303 | 29.6511 | 29.5616 | 29.3888 |
Other Liabilities, Total | 9.265 | 10.012 | 10.735 | 1.667 | 1.826 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -81.828 | -41.567 | -5.324 | -1.198 |
Cash From Operating Activities | -62.417 | -35.438 | -4.459 | -1.279 |
Cash From Operating Activities | 0.691 | 0.249 | 0.008 | 0 |
Non-Cash Items | 11.051 | 7.454 | 0.446 | 0 |
Changes in Working Capital | 7.669 | -1.574 | 0.411 | -0.081 |
Cash From Investing Activities | 27.341 | -33.355 | -0.051 | 0 |
Capital Expenditures | -1.03 | -3.171 | -0.051 | 0 |
Cash From Financing Activities | 1.239 | 153.185 | 65.966 | 1.44 |
Issuance (Retirement) of Stock, Net | 1.239 | 153.221 | 65.93 | 1.44 |
Issuance (Retirement) of Debt, Net | 0 | -0.036 | 0.036 | 0 |
Net Change in Cash | -33.837 | 84.392 | 61.456 | 0.161 |
Other Investing Cash Flow Items, Total | 28.371 | -30.184 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -29.051 | -81.828 | -56.514 | -33.624 | -16.366 |
Cash From Operating Activities | -24.044 | -62.417 | -42.216 | -25.421 | -9.994 |
Cash From Operating Activities | 0.293 | 0.691 | 0.51 | 0.336 | 0.166 |
Non-Cash Items | 3.846 | 11.051 | 8.182 | 5.297 | 2.57 |
Changes in Working Capital | 0.868 | 7.669 | 5.606 | 2.57 | 3.636 |
Cash From Investing Activities | -1.756 | 27.341 | 28.042 | 27.817 | 20.442 |
Capital Expenditures | -2.906 | -1.03 | -0.318 | -0.368 | -0.095 |
Other Investing Cash Flow Items, Total | 1.15 | 28.371 | 28.36 | 28.185 | 20.537 |
Cash From Financing Activities | 0.201 | 1.239 | 0.749 | 0.349 | 0.031 |
Issuance (Retirement) of Stock, Net | 0.201 | 1.239 | 0.749 | 0.349 | 0.031 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -25.599 | -33.837 | -13.425 | 2.745 | 10.479 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.903 | 5310165 | 315267 | 2023-06-30 | LOW |
Cormorant Asset Management, LP | Hedge Fund | 10.0217 | 3570872 | 0 | 2023-06-30 | LOW |
A2A Pharmaceuticals Inc | Corporation | 9.8227 | 3500000 | -50000 | 2023-06-01 | LOW |
Butler (Thomas Andrew) | Individual Investor | 8.3471 | 2974197 | 480790 | 2023-04-03 | |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 8.0004 | 2850670 | -265387 | 2023-06-30 | LOW |
Laurion Capital Management LP | Hedge Fund | 6.2969 | 2243687 | 1689287 | 2023-06-30 | HIGH |
Baker Bros. Advisors LP | Hedge Fund | 5.9188 | 2108949 | 0 | 2023-06-30 | LOW |
Erdtmann (Rainer M) | Individual Investor | 5.7927 | 2064030 | -480790 | 2023-04-03 | |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.4005 | 1567950 | 1511635 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2841 | 1526500 | 1069591 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.6847 | 1312909 | 223561 | 2023-06-30 | LOW |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 3.3074 | 1178471 | 328979 | 2023-06-30 | MED |
Rock Springs Capital Management LP | Hedge Fund | 2.3488 | 836898 | -460315 | 2023-06-30 | LOW |
Aisling Capital Management LP | Investment Advisor/Hedge Fund | 2.2417 | 798757 | 0 | 2023-06-30 | LOW |
Perceptive Advisors LLC | Private Equity | 2.0107 | 716441 | 391441 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2076 | 430296 | 218011 | 2023-06-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.9714 | 346113 | -135609 | 2023-06-30 | LOW |
Woodline Partners LP | Hedge Fund | 0.9589 | 341673 | 0 | 2023-06-30 | HIGH |
Millennium Management LLC | Hedge Fund | 0.9322 | 332174 | 45143 | 2023-06-30 | HIGH |
Ikarian Capital LLC | Hedge Fund | 0.7742 | 275875 | 64900 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biomea Fusion, Inc. Company profile
About Biomea Fusion Inc
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Biomea Fusion Inc revenues was not reported. Net loss increased from $5.3M to $41.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.19 to -$1.74.
Industry: | Biotechnology & Medical Research (NEC) |
900 Middlefield Road, 4th Floor
REDWOOD CITY
CALIFORNIA 94063
US
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com